A Project Report

On
Product Range Management. Evaluation of existing product
range, new product lines added and line extension strategies

Submitted in the partial fulfillment of

Masters of Business Administration
(2009-2011)

Submitted To: Submitted by:

Pradeep verma
Mr.shishir jain MBA(MM) section-B
Roll.no.43476
 DECLARATION

I have tried my level best in making this

project report useful, pragmatic & successful. I
have tried to provide the accurate information
to the best of my knowledge. The data
collected is primary, authentic & analyzed by
me.

I have got the Information which is asked to

Product manager. All other information has also
been gathered from reliable sources.
I hereby declare that project entitled “Product
Range Management. Evaluation of
existing product range, new product lines
added and line extension strategies” is
authentic. I have put in my efforts meticulously
to make this project to come up to the
expectations and pragmatically viable.

02/11/2010 PRADEEP VERMA

 ACKNOWLEDGEMENT

I express my sincere thanks to Dr. Jayant

Sonwalkar to give me an opportunity to do this
project.
I would like to express my sincere gratitude to
Mr. Shishir Jain who always made himself
available for guiding me. His inspiration is
immense. Indeed working with him was a
memorable experience.
I am grateful to Mr. Amit kumar Singh
(Production Manager) for their timely
suggestions, constructive criticism and constant
supervision during project. I also feel highly
privileged to express my indebtedness to staff
members of PDPL, my family and friends for
their valuable support and guidance in carrying
out the project.
I hope that my energy will create a positive
sign through my project report in the concern.

THANK YOU…… PRADEEP VERMA

MBA(MM) Sec-B

Executive Synopsis

Organization : Parenteral Drugs India Limited

Address : Corp. Office-Shree Ganesh Chambers, A.B.

Road, Navlakha, Indore
Tel.-0731-2401108/2401309
Fax-0731-2401307/2401052

Project Title : Product Range Management,Evaluation of

Esixting product rang, new product lines
added and line extension strategies
Reporting officer : Mr. Manoj Sharma
(Group product manager)

Methodology : Interview based on Questionnaire.

Data type : Primary & Secondary data

CONTENTS

1. INTRODUCTION

(A).Overview of Pharmaceutical Sector

(B).Overview On Company Profile

2. OBJECTIVE OF STUDY

3. DATA TYPE

4. PRODUCT MANAGER AND PRODUCT DESIGNING

5. PRODUCT MANAGER AND PRODUCT DEVELOPMENT

AND TESTING
6. PRODUCT STRATEGY

7. INTERVIEW QUESTITIONES

(A). Overview of Pharmaceutical Sector:

Accounting for two percent of the world's pharmaceutical

market, the Indian pharmaceutical sector has an estimated
market value of about US $8 billion. It's at 4th rank in terms
of total pharmaceutical production and 13th in terms of
value. It is growing at an average rate of 7.2 % and is
expected to grow to us $ 12 billion by 2010.
Over the last two years the
pharmaceutical market value has increased to about US $
355 million because of the launch of new products.
According to an estimate, 3900 new generic products have
been launched in the past two years. These have been by
and large launched by big brands in the pharma sector. And
in the year 2005 Indian pharmaceutical companies captured
 around 70% of the domestic market.
As in the present scenario, only a
few people can afford costly drugs, which have increased
price sensitivity in the pharmaceutical market. Now the
companies are trying to capture the market by introducing
high quality and low price medicines and drugs. With the
Product Patent Act, which came into action in January 2005,
this industry is able to attract big MNCs to India. Earlier these
big firms had apprehensions in launching new drug in the
Indian market. ssssssssssssssssssssssssssssssssssssss

At present, a large number of Indian pharmaceuticals

companies are looking for tie-ups with foreign firms for in-
license drugs. GlaxoSmithKline is among the top choices for
the firms that wish to launch their product in India, but do not
have any branch over here. Contract research and
pharmaceutical outsourcing are the new avenues in the
pharmaceutical market. Contract manufacturing is growing at
a very fast pace and is estimated to grow to US $30billion,
whereas contract research is estimated to reach US$6-10
billion.

Indian multinational companies like Dr.Reddy's Lab, Cipla,

Ranbaxy, etc have created awareness about the Indian
market prospects in the international pharmaceutical market.
Approvals given by Foods and Drugs Administration (FDA)
and ANDA (Abbreviated New Drug Application)/DMF (Drug
Master File) have played an important role in making India a
cost-effective and high quality product manufacturer.
Furthermore, the changes that took place in the patent law,
change of process patent to product patent, have helped in
reducing the risk of loss for intellectual property.

Industry Strengths:

 Capital Investment in Technology: Owing to the availability

of advanced technology at low costs, the companies can
produce drugs at lower costs.
 Cost Effective: The filing cost of ANDAS and DMFs is
comparatively low for the Indian companies.
 Manpower: There is a large pool of technical experts
available at modest salaries.
 Contract Research & Contract Manufacturing: There is a
good scope for contract research and contract
manufacturing.
 Infrastructure: There is a well-developed infrastructure for
the pharmaceutical industry.
 Generic Drugs: In the last few years, the generic drug-
manufacturing segment has received huge investments, in

the process making it more competitive and efficient.

Growth in Pharma Sector:

India currently holds US$ six Billion of the $550 Billion global
pharmaceutical industry; its share is increasing at 10% a year. As
compared 7% annual growth for the overall world markets, this figure
speaks of a very promising scenario.

- Domestic pharmaceutical companies will increasingly be looking for

consolidation across the value chain by forming partnerships or
mergers with companies of complementary strengths. As drug
discovery becomes more expensive, and the costs of administration
and regulatory compliance continuously rise, these partnerships will
become more central to Pharma companies' business proposition.
- The Bio Pharmaceutical market is seeing a consistent growth trend
since 2004, which saw record vaccine sales of US$ 386.3 Million and
Marketing licenses being granted for over 25 recombinant therapeutic
protein. The Diagnostics market size stands for US$138.2 Million.

Care, Concern & Cure

Company Profile:
PDPL (Parenteral Drugs india limited) Parenteral Drug is a company
that has constantly followed a path created by its own will, hard work and
determination. Dictated by a clear sense of what is right, it has always been
guided by a mind of its own and has always had its heart in the right place-
the larger interests of the common man and the long term interests of
humanity. Established in the year 1983, PDPL has dedicated itself to the
manufacturing of the best quality vital life saving drug at the lowest
possible cost.

 About Us:

Parenteral Drug is a company that has constantly followed a path

created by its own will, hard work and determination. Dictated by a clear
sense of what is right, it has always been guided by a mind of its own and
has always had its heart in the right place-the larger interests of the
 common man and the long term interests of humanity. Established in the
year 1983, PDPL has dedicated itself to the manufacturing of the best
quality vital life saving drug at the lowest possible cost. Over the years,
its path breaking innovation have lead not only to lower costs but better
quality as well because PDPL firmly believes that better quality dose not
necessarily mean higher price, it can also be achieved by indigenous
techniques and innovative technologies.

 Founder:

Never the ones follow the beaten track; this organization was blessed in
founded by man with unique vision and a courage to break conventions
for the better. Born in the tradition family of traders, this youth decided
to take the mantle of being first generation industrialist at a young age of
twenty and wrote his own success story. Retracing his eventful journey,
the important milestones, one comes across are:

...1975- Founds Prem Pharmaceuticals (Leader in glass-filled I.V. fluids)

Establishes PDPL (Pioneering Leader in Polypropylene-filled
...1983-
I.V.fluids).
...1994- Successful public issue.
Launched First single Use Eye/Ear drop Dispensers using FFS
...1996-
technology
Establishes Royal Crystal Pvt. Ltd. [now Diamond Crystal-The
...1997-
only one to make full lead Crystal Glassware in India]
Launched branded products in Tablets/Capsules/Liquids
...1998-
Orals/I.V.
...1998- Establishes Punjab Formulations.
Launched CAPD-the dialysis kit that's affordable by common
...2001-
man and is superior to the import one.
BOARD OF DIRECTORS:

1) Shri Manoharlal Gupta Chairman Cum-Managing Director

2) Shri Vinod Kumar Gupta Managing Director
3) Shri Govind Das Garg Whole-time Director
4) Shri Satish Chandra Consul Director
5) Shri Dharam Pal Khanna Director
6) Shri Dilip Kumar Sinha Director
7) Shri Dilip Kumar Panchaity Director

COMPANY SECRETARY & COMPLIANCE OFFICER

Shri Ashok Mishra

REGISTERED OFFICE
340, Laxmi Plaza, Laxmi Industrial Estate,
New Link Road, Andheri (West),
Mumbai-400 053
Maharashtra

CORPORATE OFFICE &

INVESTORS GRIEVANCES CENTRE
Shri Ganesh Chambers,
Navlakha Crossing,
Indore-452 001 (M.P.)

LOCATION OF PLANTS

1) Village Asrawad, 2) Village Bhud,

Post Dudhia, Tehsil Nalagarh,
Nemawar Road, Distt. Solan- 173 205
Indore- 453 331 Himachal Pradesh
Madhya Pradesh

 Quality Policy:
 Quality can't be imposed, it has to be inspired. Quality can't be and
accident, it has to be a scientific achievement. quality can't be a magic,
it has to be attained by understanding the magic of the imaginative
human mind. Norms and nomenclature can be drafted and framed but
only when an organization makes them a part of its culture, that its
people genuinely ingrain a quality conscious attitude in thought,
imbibe a quality control approach in action…………….
PDPL has successfully woven the threads of quality awareness in its
people's thought processes. it has and assured force of people working
on quality principles in their progress towards excellence in every
aspects of running of the company from production to products, from
ideation to realization.

Standards:

PDPL believes in appropriate and systematic methods and observes

highest standard in letter and spirit. PDPL's quality standards are truly
high. The company follow a stringent quality control policy indeed takes
quality control measures at every stage of the manufacturing process. The
quality assurance department has a well equipped laboratory with most
modern testing instrument. The quality policy has resulted in company
being conferred upon the ISO 9001:2000 and WHO GMP certification by
international bodies. not just to the products at PDPL quality is pertinent to
to every aspect pre-delivery service, delivery and post delivery service. It is
a part of the people's attitude in every step from administration production
to distribution.

Awards and rewards follow any organization that sincerely believe in

quality values. the International Gold Awards and the Udyog Ratna are a
testimony to the fact that our people have true inculcated the 'Quality eye'.
The awards are merely a reconfirmation of the fact that the path chosen is
right and the manner of following is right.
 Manufacturing:

Comprises of Sprawling plant, Pioneering products, Breakthrough process,

and Proactive people. PDPL’s modern plant, standing soberly amidst 40
Acres of green lands is located 15 Kms. From Indore in Central India. Built
on 2,50,000 Sq.ft. RCC area, it houses various state of the art as well as
indigenously design machinery that enables a variety of innovative
production processes that are routs for speedy creation and supply of a
wide spectrum of quality medicines and medical products. The fully
automated state of the art machine is imported from SIFRA, Italy for Small
Volume Parenteral.

NEWS:

Opportunity is in theair.........................................................................
There's opportunity in the air every day at PDPL. It's part of our
atmosphere of innovation, the excitement and anticipation of knowing the
next new product discovery or technological breakthrough is right around
the corner. It's the exhilaration of being able to take risks every day, the
freedom of trying your own ideas--because you're encouraged and
empowered

...around the world…………………………………………………..

PDPL develops, manufactures and markets tens of thousands of
products, from more than 30 core technologies and across some 40-plus
product divisions. We cover an amazing variety of consumer,
commercial, industrial and health needs, with operations in over 60
countries, and sales in more than 200……………………………..
...and in your hands…………………………………………………
We do everything possible to champion your creative thinking, to
streamline the process of taking your ideas from concept to
implementation. We expect 30% of our sales each year to come from
products that are less than 4 years old -- innovative new products that
begin every day with creative initiatives from you and your colleagues.

…Keep your options open........................................................................

Individuality, creativity, continuous learning, the spirit of
accomplishment, a desire to make a difference, a work environment that
maximizes your talents, skills, and career, as well as personal goals. We
expect you to be a creative thinker, a problem solver, and a challenge
seeker. You can expect PDPL to support your efforts, help you gain
knowledge with continuing education, promote your professional
development, and encourage you to achieve and reach your potential.

...in more ways than one……………………………………………

Many of our employees have long service with PDPL because we have a
promote-from-within culture, drawing on our pool of PDPL talent to fill
higher-level positions. You may also choose to move between our many
business units, or move to locations around the world, experiencing new
cultures, gaining new business experiences, developing your knowledge
and career. The magnitude and scope of what we do is so great, you can
literally re-invent your career within the same company, because at
PDPL, your options are always open.
2. Objectives Of Study:

1. Primary objective: Study on Product Range Management in

Parenteral Drugs India Limited

2. Secondary objective: Study on

a. Product Planning,
b. Test marketing,
c. Product Launch,
d. Product range management,
e. Product Positioning
 DATA SOURCE

Data is generally of two types:

1. Primary data
2. Secondary data

Primary Data are those data specially collected for problem

in hand. In this study data were collected from primary sources in
personal interview of Group Product manager.
These methods of data collection are quite popular.
In our project, we have collected primary data from PDPL at
Indore. Secondary Data are those data collected from secondry
sources like websites, magazines etc.
TESTING AND DEVELOPMENT

Responsibilities of a product manager

Plan product lines

Managing contracts and sales
Consider customer needs and direct
strategic initiatives
Strategic goals into operational tasks
Evaluating risks
Bridge between external and internal
clients\
Contingency plans
Branding

PRODUCT MANAGER
TESTING AND DEVELOPMENT

A marketer·s perspective
TESTING AND DEVELOPMENT

PRODUCT MANAGER
Product Manager & product
designing
Product Manager & product
developing and testing
PRODUCT STRATEGY
DIRECTOR
PRODUCT STRATEGY DIRECTOR
 PRODUCT PLANNING

• What is the status of product management system? When

did it started in the organization?
 It is not new field for our organization, it had started long ago.

• How many people work in product management unit?

 In Indore, Mr. Manoj Sharma works as Group Product
Manager in PDPL. Their work can not be possible without
coordination of other Department.

• What is the level of product management? (High, Middle,

Low)
 In PDPL, Product Management is on the Middle Level. But it
is very dominated in organization.

• How much product planning is done? Do they have

combined plan or have separate plan of different product?
 In PDPL, Every product has separate product planning.
It is according to the market demand, demographic (like India
& other foreign markets) & govt. rules & regulations.
Combin
ed planning for same product lines.

• When planning is done? At annual general meeting or any

other meeting?
 It can be done either annual general meeting or any meeting,
when decision makers are present. It depends on situation.
• Are there separate mangers taking care of product range?
 No

• What is the acceptance process for new product?

 According to the PLC curve, after introduction of product in
the market, if sales increase and we find less no. of complaints
and feedback from supplier, distributor & consumer.

• How new product development process is implemented?

Who initiate the process?
 New product development is implemented in following
stages.
a. Idea generation: the process of generating new ideas may
consist of brainstorming, attribute listing, focus group
disssions or problem inventory analysis. Sources of new ideas
could be:
 Customer
 Competitors
 Distributors
 Creative techniques
 External world
 R&D

b. Screening:
c. Business analysis
d. Prototype development
e. Test marketing
f. commercialization

• What is the source of data?

 Data can be Internal and external also.
• Do you have separate department for new and existing
product?
 No

• How the company accepts the new product idea?

 It is approved by high level management for increasing
market share, diversification, growth. It is very long process
which have gone through various stages.

• When it becomes a business? Who decides? How it is

decided? Is it general management or board or marketing
manager or product manager?
 It is combined efforts of high & middle level management. It
also includes technicals experts.

• Is the new product development team is temporary or

permanent?
 In PDPL, No new product development team is there. But
existing team focuses more on new product till growth, which
is permanent. Sometimes they take assistance from outside the
organization.
 TEST MARKETING
Product development stage where the product and its
marketing plan are exposed to a carefully chosen sample of
the population for deciding if to reject it before its full scale
launch. Test marketing is an experiment conducted in a field
laboratory (the test market) comprising of actual stores and
real-life buying situations, without the buyers knowing they
are participating in an evaluation exercise.

• Whether test marketing is done or not?

 it is done.

• For how many products it is done?

 It is done for every new product before full scale launching.

For ex. Apart from the single dose dispensers, the company has also
launched multi-dose Eye/Ear drops in plastic containers. The
dispensers are made using the latest and highly advanced form-fill-seal
technology. The fully automated state-of-the-art machine is imported
from Sifra, Italy.
1. Cigram Drops
Ciprofloxacin as Hydrochloride U.S.P. 0.3%
2. Gentate Drops
Gentamicin as Sulphate I.P. 0.3%
3. Gentate - B Drops
Gentamicin Sulphate I.P. ).3% & Betamethasone
Sodium Phosphate I.P. 0.

• Marketing is done in how many cities for how many

customers?
 Not to be discussed

• How much time is allotted to test marketing?

 6+ months

• What is the budget allocated for test marketing?

 Can not be disclosed

• How many cases are there where product has been

changed after test marketing?
 Against the internal policy of company

PRODUCT LAUNCH

• Do they do national launch or region launch?

 National Launch.

• If regional launch? Which region first?

 Central region for ex. Indore, Jabalpur, Ahmadabad, Bhopal
etc

• How many cities with how much duration?

 In india, 35 cities are there. Where product can be launched.
• Details of 1 product launch within 3 years?
 The Company has introduced the first ever single use preservative free
sterile , disposable Eye/ Ear dispensers in India using ‘form-fill-seal’
technology….
5. Flufen Eye Drops
Flurbiprofen Sodium I.P. 0.03% w/v
6. Ikleen Eye Drops
Hydroxypropyl Methylcellulose - 0.7% Boric Acid & Sodium
Borate
• What was the duration of the launch?
 6- 18 months

• What was the budget of the launch?

 Can not disclose. but it is competitive price.

• Which media was selected of for the launch?

 Electronic media, Mouth publicity through M.R. etc

• For how many months launch was tracked?

 It varies. Sometimes it was 6- 8 months or more than it.

• What measure has been taken to track the launch?

 Supplier feedback
 Sales volume
 Retailers response
 PRODUCT RANGE MANAGEMENT

• What is the product range in the company?

• Product:

Solid & liquid orales:

These include antibiotics, anti-ulcerant, anti- bacterial, anti-

inflammatory/analgesics, anti-cold, multi-vitamins and cardiac
Products. Liquid preparations in cough syrup anti-cold and other
pediatric products have recently been launched.

01. Tab.Ciprodex (Ciprofloxacin 250/500/750 mg)

02. Tab.Ciprodex TZ (Ciprofloxacin 500mg+Tinidazole 600 mg)
03. Odox DT [Doxycycline(as Monohydrate) 100 mg]
04. Tab.PD-Nor TZ (Norfloxacin 400 mg + tinidazole 600 mg)
05. Tab.PD Roxil LB ( Cefadroxil 125/250/500 mg + Lactobacillus
20/30/60 Million Spores.)
06. Tab. PD Rox (Roxithromycin 150 mg)
07. Cap. PD Mox (Amoxycillin 250/500 mg)
08. Tab. PD Mox LB ( Amoxycillin 125/250/500 mg +
Lactobacillus 60 Million Spores)
09. Tab. Ceftiwin (Cefixime 50 DT / 100 DT /200
mg+Lactobacillus 20/40/60 Million spores.)
10. Tab.Oflodex -(Ofloxacin 100/200/400 mg)

11. Tab.Oflodex TZ (Ofloxacin 200 mg + Tinidazole 600 mg )

12. Tab.Spradex (Spraafloxacin 100/200 mg)
13. Ceface ( Cefuroxime 125/250/500 mg)
14. PD Roxil dry syrup (Cefadroxil 125 mg / 5 ml)
15. Ceftiwin dry syrup (Cefixime 50 mg/5 ml)
ANTIULCERANT :

16.Tab.Ranizac (Ranitidine Hydrochloride 150 mg)

17.Cap.Omenoz –20 (Omeprazole 20 mg)

ANALGESICS ANTI-INFLAMMATORY:

18. Tab.PD Flam (Ibuprofen 400 mg + Paracetamol 325 mg )

19. Tab.Dolofenac (Diclofenac Sodium 50 mg + Paracetamol 500
mg )
20. Tab.Nimpic -IR (Nimesulide 100 mg )
21. Nimpic Suspension (Nimesulide 50 mg / 5 ml)
22. Tablet Nimpic –P( Nimesulide 100mg + Paracetamol 500mg)
23. Pidimol Syrup (Paracetamol 125 mg/ 5ml)
24. Valpic (Valdecoxib - 10mg/ 20mg)
25. Rofpic (Rofecoxib - 12.5mg/ 25mg)

MULTIVITAMINS AND MINERALS:

26. Tab. Recmin

Vitamin B1 I.P. 10 mg
Vitamin B2 I.P. 10 mg
Vitamin B6 I.P. 3 mg
Vitamin B12 I.P. 15 mcg
Niacinamide I.P. 100 mg
Calcium Pantothenate I.P. 20 mg
Folic Acid I.P. 1.5 mg
Vitamin C I.P. 75 mg
Lactobacillus acidophillus 1000 lac

27.Recmin Syrup.
Each 5 ml contains:
Thiamine HCl 2 mg
Riboflavine Sodium 5 Phosphate 2.54 mg
Pyridoxine HCl 2 mg
Niacinamide 20 mg
D-Panthenol 6 mg
Ascorbic acid 75 mg

28. Tab Calset ( 1.25 gm Calcium Carbonate from organic

source {Oyster Shell } equivalent to elemental calcium
500 mg + Vitmin D3 I.P. 250 iu )

29. Tab. Antoxy -1

Vitamin A (as acetate ) I.P. 5000 iu
Vitamin E Acetate I.P. 25 iu
Ascorbic Acid IP 100 mg
Thaimine Mononitrate I.P.10 mg
Riboflavin I.P. 10 mg
Pyridoxine Hydrochloride I.P. 3 mg
Cynocobalamin I.P.5 mcg
Niacinamide 50 mg
Folic Acid I.P. 1 mg
Calcium Pantothenate I.P. 12.5 mg
Zinc Oxide equivalent to elemental zinc 15 mg
Cupric Oxide equivalent to elemental copper 2.5mg
Manganese Chloride equivalent to Elemental manganese-1.4 mg
Chromium Chloride equivalent to elemental chromium 65 mcg
Sodium Selenate equivalent to elemental selenium 60 mcg

ANXIOLYTIC:

30. Tab.Anzofree (Alprazolam 0.25/0.5 mg)

Tab.Anzofree-SR (Alprazolam 0.5 mg/1 mg/ 1.5 mg )

ANTIPROTOZOAL:
31. Tab Trisec Forte ( Secnidazole 1 gm )
32. Tab. Trisec (Secnidazole 0.5 gm)

ANTICOLD:

33. Tab.Bycold
(Chlopheniramine maleate I.P. 4 mg
Phenylpropanolamine HCI I.P. 25 mg
Peracetamole I.P. 500 mg)

34. Bycold Syrup

Each 5ml contains
(Chlorpheniramine maleate I.P. 2 mg
Phenylpropanolamine HCI I.P. 12.5 mg
Peracetamole I.P. 125 mg)

ANTHELMINTIC:

35. Tab. Wornet ( Albandazole 400 mg )

36. Wornet Sups.(Albendazole 400 mg/10 ml)

ANTI-HISTAMINIC:

37. Tab. Fexoday (Fexofenadine Hydrochloride 120/1180 mg)

MUSCLE RELAXANT:

38. Tab.Tizadin (Tizanidine 2 mg/4 mg)

39. Tab.Nimpic –MR(Nimesulide 100mg + Tizanidine 2mg)
40. Tab.Dolofenac-MR(Diclofenac 50mg + Paracetamol 500mg +
Chlorzoxazone 500mg)
41. Tab.Dolofenac-Plus(Diclofenac 50mg + Paracetamol 325mg +
Chlorzoxazone 250mg)
CARDIAC:

42. Tab. Amvasc ( Amlodipine Besylate 2.5 mg/5mg/10mg)

43. Tab. Amvasc AT ( Amlodipine Besylate 5 mg+Atenolol 50 mg)
44 Tab. Atese (Atenolol 50 mg/100 mg)
45. Tab.Isbid (Isosorbide 5 Mononitrate 10 mg / 20 mg)
46. Tab. Safepril (Enalapril Maleate 2.5 mg/5 mg /10 mg)
47. Tab. Hopril( Ramipril 1.25/2.5/5/10mg)
48. Tab. Atzaar(Losartan potassium 25/50mg)

ANTIDIABETIC:
49. Gliz-500 (Metformin 500mg)
50. Glic-M (Gliclazide 80mg+ Metformin 500mg)

COUGH SYRUP:

51. Syp. Silenser DX

Each 5 ml contains
Dextroomethrophan
Hydrobromide-10mg
Chlorpheniramine maleate-4 mg

52. Syp. Silenser

Each 5 ml contains
Codeine Phosphate - 10mg
Chlorpheniramine maleate-4mg

Appetite Enhancer:

53.Toncyp Syrup
(Cyproheptadine HCl 2 mg +
Tricholine Citrate 275 mg
Sorbitol Solution (70%) IP 3.575 gm/5ml.
Injections:

54.Cefnid 500 mg / 1g (Ceftriaxone 500 mg / 1g)

55.M-Cin 100 / 500 mg (Amikacin 100/500 mg)
56.Ceface 250/750mg/1.5 g (Cefuroxime 250/750 mg/1.5g)
57.Cefnep 250 mg/1g (Ceftazidime 250 mg/1g)

Eye drops:

Apart from the single dose dispensers, the company has also
launched multi-dose Eye/Ear drops in plastic containers. The
dispensers are made using the latest and highly advanced form-
fill-seal technology. The fully automated state-of-the-art
machine is imported from Sifra, Italy.

1. Cigram Drops
Ciprofloxacin as Hydrochloride U.S.P. 0.3%
2. Gentate Drops
Gentamicin as Sulphate I.P. 0.3%
3. Gentate - B Drops
Gentamicin Sulphate I.P. ).3% & Betamethasone
Sodium Phosphate I.P. 0.1%
4. Ocuroid Drops
Dexamethasone Sodium Phosphate I.P. 0.1% and
Neomycin Sulphate I.P. 0.5%
5. Flufen Eye Drops
Flurbiprofen Sodium I.P. 0.03% w/v
6. Ikleen Eye Drops
Hydroxypropyl Methylcellulose - 0.7% Boric Acid & Sodium
Borate
I.V. Fluids:

Various therapeutic segment of I.V. fluids being produced are:

.Electrolytes
.Antibacterial
.Energy replenisher
.Irrigation solution
.Osmotic diuretic
.Dialysis solution

PDPL is the pioneer company making 400 mg Ciprofloxacin

infusion in 200 ml with 5% dextose. The I.V. fluids are packed in
size ranging from 100 ml to 3 litre and dialysis solution up to 10
litres Water for injection is manufactured with the help of hi-tech
From-Fill-seal machine ranging from 1 ml to 10 ml.

1. Dextrose Inj. I.P. 5% 500ml/1000ml

02. Dextrose Inj. I.P. 10% 500ml/1000ml
03. Dextrose Inj. I.P. 20% 500ml
04. Dextrose Inj. I.P. 50% 100ml
05. Dextrose 5% in 0.9% sod.chloride Inj. 500ml/1000ml
06. Dextrose 10% in 0.9% sod.chloride Inj. 500ml/1000ml
07. Dextrose 5% in 0.45% sod.chloride Inj. 500ml/1000ml
08. Dextrose 5% in 0.2% sod.chloride Inj. 500ml/1000ml
09. 0.9% Sodium Chloride Inj. 500ml/1000ml/2000ml/3000ml
10. Ringer Lactate Inj 500ml/1000ml
11. Multiple Electrolyte 'G' 500 ml
12. Multiple Electrolyte 'P' 500 ml/1000ml
13. Multiple Electrolyte 'E' 500 ml
14. Multiple Electrolyte 'M' 500 ml/1000 ml
15. PD-Zole-D 500 ml
16. Metronidazole Injection 100 ml
17. Ciprofloxacin Injection USP 100 ml
18. Intraperitoneal Dialysis Solution 1000 ml/2000 ml
 19. Mannitol-10% 300 ml/350 ml
20. Mannitol-20% 100 ml/300 ml/350 ml
21. 1.5%Glycine 1000 ml/2000 ml/3000 ml
22. P.D. Invert (10% Invert Sugar) 500 ml
23. Oflodex IV (Ofloxacin 2 mg per ml ) 100 ml
24. Ciprodex IV (Ciprofloxacin 2 mg per ml +5% Dextrose)
200 ml
25. Tinpidi IV ( Tinidazole 2 mg per ml) 400 ml
26. Water for injection [range :1ml -10ml ]
27. Concentrated Haemodialysis solution (Bicarbonate &
acetate type)

2. What are the criteria for evaluating product performance?

 Marketable
 Sustainability

• Who takes the decisions of promoting selected group of

product in a product range?
 Product manager

• How new lines are added in the product range?

 With the help of R & D
 PRODUCT POSITIONING

• How positioning strategies is decided for each product?

 Positioning by specific product attributes

 Positioning by distinct benefits to users
 Positioning by specific usage
 Positioning by price/quality

• Is the positioning strategy is for product line or individual

product?
 For product

• Do they have national positioning or regional positioning?

 National positioning

Thanking you……………….